Risk and Healthcare Costs of Chemotherapy-Induced Neutropenic Complications in Women with Metastatic Breast Cancer | Zendy

Derek Weycker | Zendy; John Edelsberg | Zendy; Alex Kartashov | Zendy; Rich Barron | Zendy; Gary H. Lyman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Risk and Healthcare Costs of Chemotherapy-Induced Neutropenic Complications in Women with Metastatic Breast Cancer

Author(s) -

Derek Weycker,

John Edelsberg,

Alex Kartashov,

Rich Barron,

Gary H. Lyman

Publication year - 2012

Publication title -

chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.539

H-Index - 54

eISSN - 1421-9794

pISSN - 0009-3157

DOI - 10.1159/000335604

Subject(s) - medicine , chemotherapy , breast cancer , cyclophosphamide , docetaxel , metastatic breast cancer , regimen , retrospective cohort study , cancer , chemotherapy regimen , oncology , population , cohort , surgery , environmental health

The burden of chemotherapy-induced neutropenic complications (CINC) in women with metastatic breast cancer (MBC) is largely unknown and may differ across cancer populations due to variation in the characteristics of patients, their disease and their treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research